Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Recruiting
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Recruiting
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Not Yet Recruiting
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Coming Soon
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Ocuphire Pharma Inc.

Nov 9, 2020

Biotech entrepreneur Sooch completes merger to take latest company public

Nov 6, 2020

Mediaplanet’s 2020 Vision Health Edition Features Night Vision Disturbances and Ocuphire Pharma’s Leadership in Investigating Potential Treatments for the Condition

Sep 30, 2020

Sooch raises $5 million for new venture, ophthalmology Pharma company Ocuphire

Jul 21, 2020

Farmington Hills biotech company Ocuphire strikes deal that will put it on stock exchange

Jun 24, 2020
RSS
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use